by The influenza vaccine market size is poised to grow by USD 15.66 billion by 2032 from USD 7.77 billion in 2023, exhibiting a CAGR of 8.10% during the forecast period 2023-2032.
Key Takeaways
- North America contributed more than 47% of the market share in 2022.
- Asia-Pacific is estimated to witness the fastest CAGR between 2023 and 2032.
- By vaccine type, the quadrivalent segment has held the largest market share of 65% in 2022.
- By vaccine type, the trivalent segment is anticipated to grow at a remarkable CAGR of 10.1% between 2023 and 2032.
- By technology, the egg-based segment generated over 69% of the market share in 2022.
- By technology, the cell culture segment is expected to expand at the fastest CAGR over the projected period.
- By age group, the pediatric segment held the largest market share of 59% in 2022.
- By age group, the adult segment is expected to expand at the fastest CAGR over the projected period.
- By route of administration, the nasal spray segment generated over 53% of the market share in 2022.
- By route of administration, the injection segment is expected to expand at the fastest CAGR over the projected period.
Precedence Research has conducted a comprehensive market study that provides valuable insights into the performance of the market during the forecast period. The study identifies significant trends that are shaping the growth of the Influenza vaccine market. In this recently published report, essential dynamics such as drivers, restraints, and opportunities are highlighted for both established market players and emerging participants involved in production and supply.
To begin with, the Influenza vaccine Market report features an executive summary that offers a concise overview of the marketplace. It outlines the key players and industry categories expected to have an impact on the market in the coming years. The executive summary provides an unbiased summary of the market.
Get a Sample Report: https://www.precedenceresearch.com/sample/3637
Influenza Vaccine Market Scope
| Report Coverage | Details |
| Growth Rate from 2023 to 2032 | CAGR of 8.10% |
| Market Size in 2023 | USD 7.77 Billion |
| Market Size by 2032 | USD 15.66 Billion |
| Largest Market | North America |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Segments Covered | By Vaccine Type, By Technology, By Age Group, and By Route of Administration |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Read More: Medical Alert Systems Market Poised to Exceed $20.92 Bn By 2032
The empirical study on the global Influenza vaccine market primarily focuses on the drivers in subsequent sections. It demonstrates how changing demographics are projected to influence the supply and demand dynamics in the Influenza vaccine Market. Our market report for the Influenza vaccine market also delves into the significant rules and regulations that are likely to impact the future growth of this sector. Moreover, in order to comprehend the underlying demand factors, industry experts have provided insights into its fundamental origins.
Influenza Vaccine Market Players
- Sanofi Pasteur
- GlaxoSmithKline plc (GSK)
- Seqirus (a CSL Limited Company)
- Pfizer Inc.
- AstraZeneca
- BiondVax Pharmaceuticals Ltd.
- Novavax, Inc.
- Bharat Biotech
- Johnson & Johnson
- MedImmune, LLC (AstraZeneca)
- FluGen
- Mitsubishi Tanabe Pharma Corporation
- Emergent BioSolutions
- Sinovac Biotech Ltd.
- Bio Farma
Data Sources and Methodology
To gather comprehensive insights on the Global Influenza vaccine Market, we relied on a range of data sources and followed a well-defined methodology. Our approach involved interactions with industry experts and key stakeholders across the market’s value chain, including management organizations, processing organizations, and analytics service providers.
We followed a rigorous data analysis process to ensure the quality and credibility of our research. The gathered information was carefully evaluated, and relevant quantitative data was subjected to statistical analysis. By employing robust analytical techniques, we were able to derive meaningful insights and present a comprehensive overview of the Global Influenza vaccine Market.
The most resonating, simple, genuine, and important causes because of which you must decide to buy the Influenza vaccine market report exclusively from precedence research
- The research report has been meticulously crafted to provide comprehensive knowledge on essential marketing strategies and a holistic understanding of crucial marketing plans spanning the forecasted period from 2023 to 2032.
Key Features of the Report:
- Comprehensive Coverage: The report extensively encompasses a detailed explanation of highly effective analytical marketing methods applicable to companies across all industry sectors.
- Decision-Making Enhancement: It outlines a concise overview of the decision-making process while highlighting key techniques to enhance it, ensuring favorable business outcomes in the future.
- Articulated R&D Approach: The report presents a well-defined approach to conducting research and development (R&D) activities, enabling accurate data acquisition on current and future marketing conditions.
Market Segmentation:
By Vaccine Type
- Quadrivalent
- Trivalent
By Technology
- Egg-based
- Cell culture
By Age Group
- Pediatric
- Adult
By Route of Administration
- Injection
- Nasal Spray
By Geography
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa
Reasons to Consider Purchasing the Report:
- Enhance your market research capabilities by accessing this comprehensive and precise report on the global Influenza vaccine market.
- Gain a thorough understanding of the overall market landscape and be prepared to overcome challenges while ensuring robust growth.
- Benefit from in-depth research and analysis of the latest trends shaping the global Influenza vaccine market.
- Obtain detailed insights into evolving market trends, current and future technologies, and strategic approaches employed by key players in the global Influenza vaccine market.
- Receive valuable recommendations and guidance for both new entrants and established players seeking further market expansion.
- Discover not only the cutting-edge technological advancements in the global Influenza vaccine market but also the strategic plans of industry leaders.
Table of Content
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Influenza Vaccine Market
5.1. COVID-19 Landscape: Influenza Vaccine Industry Impact
5.2. COVID 19 – Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Influenza Vaccine Market, By Vaccine Type
8.1. Influenza Vaccine Market Revenue and Volume Forecast, by Vaccine Type, 2023-2032
8.1.1. Quadrivalent
8.1.1.1. Market Revenue and Volume Forecast (2020-2032)
8.1.2. Trivalent
8.1.2.1. Market Revenue and Volume Forecast (2020-2032)
Chapter 9. Global Influenza Vaccine Market, By Technology
9.1. Influenza Vaccine Market Revenue and Volume Forecast, by Technology, 2023-2032
9.1.1. Egg-based
9.1.1.1. Market Revenue and Volume Forecast (2020-2032)
9.1.2. Cell culture
9.1.2.1. Market Revenue and Volume Forecast (2020-2032)
Chapter 10. Global Influenza Vaccine Market, By Age Group
10.1. Influenza Vaccine Market Revenue and Volume Forecast, by Age Group, 2023-2032
10.1.1. Pediatric
10.1.1.1. Market Revenue and Volume Forecast (2020-2032)
10.1.2. Adult
10.1.2.1. Market Revenue and Volume Forecast (2020-2032)
Chapter 11. Global Influenza Vaccine Market, By Route of Administration
11.1. Influenza Vaccine Market Revenue and Volume Forecast, by Route of Administration, 2023-2032
11.1.1. Injection
11.1.1.1. Market Revenue and Volume Forecast (2020-2032)
11.1.2. Nasal Spray
11.1.2.1. Market Revenue and Volume Forecast (2020-2032)
Chapter 12. Global Influenza Vaccine Market, Regional Estimates and Trend Forecast
12.1. North America
12.1.1. Market Revenue and Volume Forecast, by Vaccine Type (2020-2032)
12.1.2. Market Revenue and Volume Forecast, by Technology (2020-2032)
12.1.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)
12.1.4. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
12.1.5. U.S.
12.1.5.1. Market Revenue and Volume Forecast, by Vaccine Type (2020-2032)
12.1.5.2. Market Revenue and Volume Forecast, by Technology (2020-2032)
12.1.5.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)
12.1.5.4. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Volume Forecast, by Vaccine Type (2020-2032)
12.1.6.2. Market Revenue and Volume Forecast, by Technology (2020-2032)
12.1.6.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)
12.1.6.4. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
12.2. Europe
12.2.1. Market Revenue and Volume Forecast, by Vaccine Type (2020-2032)
12.2.2. Market Revenue and Volume Forecast, by Technology (2020-2032)
12.2.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)
12.2.4. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
12.2.5. UK
12.2.5.1. Market Revenue and Volume Forecast, by Vaccine Type (2020-2032)
12.2.5.2. Market Revenue and Volume Forecast, by Technology (2020-2032)
12.2.5.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)
12.2.5.4. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
12.2.6. Germany
12.2.6.1. Market Revenue and Volume Forecast, by Vaccine Type (2020-2032)
12.2.6.2. Market Revenue and Volume Forecast, by Technology (2020-2032)
12.2.6.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)
12.2.6.4. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
12.2.7. France
12.2.7.1. Market Revenue and Volume Forecast, by Vaccine Type (2020-2032)
12.2.7.2. Market Revenue and Volume Forecast, by Technology (2020-2032)
12.2.7.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)
12.2.7.4. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Volume Forecast, by Vaccine Type (2020-2032)
12.2.8.2. Market Revenue and Volume Forecast, by Technology (2020-2032)
12.2.8.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)
12.2.8.4. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
12.3. APAC
12.3.1. Market Revenue and Volume Forecast, by Vaccine Type (2020-2032)
12.3.2. Market Revenue and Volume Forecast, by Technology (2020-2032)
12.3.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)
12.3.4. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
12.3.5. India
12.3.5.1. Market Revenue and Volume Forecast, by Vaccine Type (2020-2032)
12.3.5.2. Market Revenue and Volume Forecast, by Technology (2020-2032)
12.3.5.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)
12.3.5.4. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
12.3.6. China
12.3.6.1. Market Revenue and Volume Forecast, by Vaccine Type (2020-2032)
12.3.6.2. Market Revenue and Volume Forecast, by Technology (2020-2032)
12.3.6.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)
12.3.6.4. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
12.3.7. Japan
12.3.7.1. Market Revenue and Volume Forecast, by Vaccine Type (2020-2032)
12.3.7.2. Market Revenue and Volume Forecast, by Technology (2020-2032)
12.3.7.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)
12.3.7.4. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Volume Forecast, by Vaccine Type (2020-2032)
12.3.8.2. Market Revenue and Volume Forecast, by Technology (2020-2032)
12.3.8.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)
12.3.8.4. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
12.4. MEA
12.4.1. Market Revenue and Volume Forecast, by Vaccine Type (2020-2032)
12.4.2. Market Revenue and Volume Forecast, by Technology (2020-2032)
12.4.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)
12.4.4. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
12.4.5. GCC
12.4.5.1. Market Revenue and Volume Forecast, by Vaccine Type (2020-2032)
12.4.5.2. Market Revenue and Volume Forecast, by Technology (2020-2032)
12.4.5.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)
12.4.5.4. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
12.4.6. North Africa
12.4.6.1. Market Revenue and Volume Forecast, by Vaccine Type (2020-2032)
12.4.6.2. Market Revenue and Volume Forecast, by Technology (2020-2032)
12.4.6.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)
12.4.6.4. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
12.4.7. South Africa
12.4.7.1. Market Revenue and Volume Forecast, by Vaccine Type (2020-2032)
12.4.7.2. Market Revenue and Volume Forecast, by Technology (2020-2032)
12.4.7.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)
12.4.7.4. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Volume Forecast, by Vaccine Type (2020-2032)
12.4.8.2. Market Revenue and Volume Forecast, by Technology (2020-2032)
12.4.8.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)
12.4.8.4. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
12.5. Latin America
12.5.1. Market Revenue and Volume Forecast, by Vaccine Type (2020-2032)
12.5.2. Market Revenue and Volume Forecast, by Technology (2020-2032)
12.5.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)
12.5.4. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
12.5.5. Brazil
12.5.5.1. Market Revenue and Volume Forecast, by Vaccine Type (2020-2032)
12.5.5.2. Market Revenue and Volume Forecast, by Technology (2020-2032)
12.5.5.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)
12.5.5.4. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Volume Forecast, by Vaccine Type (2020-2032)
12.5.6.2. Market Revenue and Volume Forecast, by Technology (2020-2032)
12.5.6.3. Market Revenue and Volume Forecast, by Age Group (2020-2032)
12.5.6.4. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
Chapter 13. Company Profiles
13.1. Sanofi Pasteur
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. GlaxoSmithKline plc (GSK)
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Seqirus (a CSL Limited Company)
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Pfizer Inc.
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. AstraZeneca
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. BiondVax Pharmaceuticals Ltd.
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Novavax, Inc.
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Bharat Biotech
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Johnson & Johnson
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. MedImmune, LLC (AstraZeneca)
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
Chapter 14. Research Methodology
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
Chapter 15. Appendix
15.1. About Us
15.2. Glossary of Terms
Unlocking Market Insights through Data Excellence
The “Precedence Statistics” flexible dashboard is a powerful tool that offers real-time news updates, economic and market forecasts, and customizable reports. It can be configured to support a wide range of analysis styles and strategic planning needs. This tool empowers users to stay informed and make data-driven decisions in various scenarios, making it a valuable asset for businesses and professionals looking to stay ahead in today’s dynamic and data-driven world.
Access our Premium Real Time Data Intelligence Tool, Visit: www.precedencestatistics.com
Precedence Statistics – Empowering Your Data Insights
Contact Us
Precedence Research
Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
